OUR PURPOSE Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. OUR CREDENTIALS Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016 (under symbol KURN). With additional operations in the Netherlands and the USA, we continue to grow our global team. To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to advance bone healing. • Listing on the 𝗦𝗜𝗫 𝗦𝘄𝗶𝘀𝘀 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲 under the symbol KURN since 2016 • A commercial & research footprint that spans >𝟮𝟬 𝗺𝗮𝗿𝗸𝗲𝘁𝘀 • Dozens of 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗲𝘅𝗽𝗲𝗿𝘁 𝗮𝗱𝘃𝗶𝘀𝗲𝗿𝘀 • >𝟮𝟱 orthobiologics-related 𝗽𝗮𝘁𝗲𝗻𝘁𝘀 • >𝟰𝟬𝟬 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗲𝗱 in Level I, randomized controlled clinical trials • >𝟮𝟬 well-controlled 𝗟𝗲𝘃𝗲𝗹 𝗜-𝗜𝗩 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗲𝗱, including 6 that are complete¹ • Published Level I evidence published in 𝑆𝑝𝑖𝑛𝑒 CONTACT KUROS TO FIND OUT MORE >>>>
新增 营销与公关 活动 — 刚出现 54 个新信号。
该公司进入各个市场的顺序 — 从最早到最新
Kuros Biosciences Achieves Profitability Growth
𝗞𝘂𝗿𝗼𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱 𝘁𝗼𝗱𝗮𝘆 𝟰𝟱% 𝗛𝟭 𝟮𝟬𝟮𝟲 𝘆𝗲𝗮𝗿-𝗼𝘃𝗲𝗿-𝘆𝗲𝗮𝗿 𝘀𝗮𝗹𝗲𝘀 𝗴𝗿𝗼𝘄𝘁𝗵 𝗮𝗻𝗱 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝘀 𝗼𝘃𝗲𝗿𝗮𝗹𝗹 𝗽𝗿𝗼𝗳𝗶𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 A dozen milestones that mark our next phase of scale – see what’s driving the momentum: 1) Total Medical Device sales +45% to USD 92.4M 2) EBITDA increased 46% to USD 7.4M3) Adjusted EBITDA increased 61% to USD 12.5M (13.6% margin) 4) Net profit amounted to USD 4.4M5) Cash on track; funding U.S. and Netherlands expans ...
注册以查看完整信号动态
Kuros Biosciences 的国际扩张与竞争对手的对比情况
Kuros Biosciences你条形图显示所对比公司之间的相对规模。
5 项指标| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Kuros Biosciences你 | 2 | 0 | +1767% | 59 | 56 |
最近 90 天新增 7 个职位。 以 Information Technology 为主，集中在 荷兰。
Bilthoven, Utrecht, Netherlands · 3天前
Supply Chain Analyst
San Francisco, CA · 2周前
Regional Sales Manager - Northern California
Bilthoven, Utrecht, Netherlands · 3周前
Warehouse and Customer Service Employee
在技术栈中检测到 28 项技术。
覆盖 56 个市场 的 2 个进行中的广告系列。
已结束
已结束最近 90 天获 3 次提及。
瑞士医疗科技公司Kuros Biosciences报告2026年上半年收入增长45%至9240万瑞郎,净利润440万瑞郎,由MagnetOs产品线推动。
Kuros Biosciences在乔治亚州开设生产设施,获瑞银买入评级。MagnetOs骨替代材料推动美国增长,第一季销售增长51%至4340万美元,目标2028年达3.3亿美元。
Kuros Biosciences将在苏黎世资本市场日展示MagnetOs™商业动能及可扩展的优质增长计划。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Kuros Biosciences 的业务、市场和增长信号的快速解答。
